Feeding Timing May Protect the Brain by Preserving Gut Microbiome in ICU Patients

Acute brain injury—whether traumatic, vascular, or secondary (as in sepsis-associated encephalopathy or ICU delirium)—carries lasting cognitive and functional consequences for survivors. Once primary injury occurs, few therapies meaningfully alter the trajectory of secondary neurological damage. This 2026 narrative review from researchers at the University of Bari and Université Libre de Bruxelles proposes that nutritional timing may represent a modifiable lever for reducing neuroinflammation through the gut–brain axis.

The gut microbiome (GM) degrades rapidly in ICU patients—within as little as 6 hours of admission—shifting from a diverse commensal community toward a 'pathobiota' dominated by opportunistic organisms such as Enterococcus and Klebsiella, while beneficial taxa like Lachnospiraceae and Ruminococcaceae are depleted. Brain injury accelerates this process through catecholamine surges, impaired splanchnic perfusion, reduced gut motility, and neurocritical interventions including sedation and vasoactive drugs. The resulting dysbiosis impairs production of short-chain fatty acids (SCFAs) like butyrate, which normally stabilize the blood–brain barrier, modulate microglial phenotype, and suppress NF-κB and NLRP3 inflammasome signaling. Loss of these protective metabolites feeds a neuroinflammatory loop measurable via biomarkers such as GFAP, NfL, and S100B.

The review's central mechanistic argument is that continuous enteral feeding—the dominant ICU practice—abolishes circadian feeding-fasting cycles that normally entrain the GM, sustain ketogenesis, promote autophagy, and regulate insulin signaling. Intermittent or time-restricted feeding strategies could theoretically restore these fasting-state biological programs. The authors surveyed randomized trials, crossover pilot studies, and guideline statements comparing continuous, cyclic, and intermittent enteral regimens. Findings were sobering: no consistent mortality benefit was found for intermittent versus continuous feeding; pooled analyses actually reported more diarrhea, abdominal distension, and longer ICU stays with intermittent schedules, especially in ventilated patients. However, pilot studies confirmed that 12-hour macronutrient interruptions reliably trigger measurable metabolic fasting responses. One RCT with GM endpoints demonstrated feasible modulation of gut microbial taxa and 58 differentially abundant serum metabolites using a sequential continuous-to-intermittent feeding protocol.

Critically, only five identified studies enrolled dedicated brain-injured cohorts, and none measured GM composition, neuroinflammatory markers, or gut–brain mechanistic endpoints under different feeding schedules. This is the central evidentiary gap the authors highlight. The biological case for non-continuous feeding preserving neuroimmune function is mechanistically coherent but empirically untested in this population.

The authors conclude by calling for phased translational trials specifically in brain-injured and neurologically at-risk ICU patients, pairing GM sequencing, SCFA profiling, and neuroinflammatory biomarkers with clinical safety endpoints. They explicitly caution that this review makes a mechanistic, not empirical, argument—no clinical evidence yet supports non-continuous feeding as a neuroprotective strategy.